Biofrontera Yönetim

Yönetim kriter kontrolleri 1/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Recent updates

Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Oct 13

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

May 21

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

Mar 07

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Dec 07

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Jun 08

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 14

CEO

Biofrontera CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pilar de la Huerta Martinez	CFO & Member of Executive Board	2.2yrs	€369.00k	Veri yok
Ludwig Lutter	Member of the Executive Board	3.7yrs	€435.65k	Veri yok
Alexander Richardson	Head of UK Sales Team	6.5yrs	Veri yok	Veri yok
Matthias Naumann	Head of Sales & Marketing - Europe	4.8yrs	Veri yok	Veri yok
Montserrat Foguet	Managing Director of Biofrontera UK Ltd.	1.9yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: B8FK's management team is considered experienced (3.7 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Humphrey Rang	Head of the Scientific Advisory Board	no data	Veri yok	Veri yok
Wilhelm Zours	Chairman of the Supervisory Board	2.9yrs	€44.00k	Veri yok
Heikki Lanckriet	Member of the Supervisory Board	2.9yrs	€22.00k	Veri yok
Helge Lubenow	Member of the Supervisory Board	2.9yrs	€47.00k	Veri yok
Karlheinz Schmelig	Member of the Supervisory Board	2.9yrs	€28.00k	Veri yok
Jorgen Tielmann	Vice-Chairman of the Supervisory Board	2.9yrs	€33.00k	Veri yok
Karin Lergenmuller	Member of Supervisory Board	2.3yrs	€23.00k	Veri yok

2.9yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: B8FK's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Biofrontera Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Biofrontera AG, Annual General Meeting, Aug 28, 2024

Biofrontera AG, Annual General Meeting, Jun 20, 2023

Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd

Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board

Biofrontera AG Announces Appointment of Pilar de la Huerta Martinez as New Chief Financial Officer

Biofrontera AG Appoints Paul Böckmann to Management Board

Recent updates

Biofrontera AG (ETR:B8FK) Surges 30% Yet Its Low P/S Is No Reason For Excitement

New major risk - Financial position

Second quarter 2024 earnings released: €0.023 loss per share (vs €0.12 profit in 2Q 2023)

Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024

Biofrontera AG, Annual General Meeting, Aug 28, 2024

New major risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 19%

First quarter 2024 earnings released: €0.04 loss per share (vs €1.05 loss in 1Q 2023)

Biofrontera AG (ETR:B8FK) Not Doing Enough For Some Investors As Its Shares Slump 47%

Biofrontera AG to Report Q1, 2024 Results on May 31, 2024

Full year 2023 earnings released: €0.01 loss per share (vs €0.77 loss in FY 2022)

Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023

Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023

Biofrontera Launches Novel Belixos Active Care

Biofrontera AG to Report Q1, 2023 Results on May 31, 2023

Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial

Biofrontera AG, Annual General Meeting, Jun 20, 2023

Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd

Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022

Biofrontera AD Shares - Sponsored to Be Deleted from OTC Equity

Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board

Biofrontera AG Announces Appointment of Pilar de la Huerta Martinez as New Chief Financial Officer

Biofrontera AG to Report First Half, 2022 Results on Aug 23, 2022

Biofrontera AG Appoints Paul Böckmann to Management Board

Biofrontera AG to Report Q1, 2022 Results on May 17, 2022

Biofrontera AG Provides Earnings Guidance for the Year 2022

Biofrontera AG to Report Fiscal Year 2021 Results on Apr 28, 2022

Biofrontera AG Proposes Revenue Guidance for the Year 2022

Biofrontera AG Resigns Franca Ruhwedel as Member of the Supervisory Board

Biofrontera AG Decides to Delist ADS from Nasdaq

Biofrontera AG Announces Progress of Phase Iii Study for the Treatment of sBCC with Ameluz®

Forecast to breakeven in 2024

Biofrontera AG Enrolls First Patient to Phase IIb Clinical Study Evaluating Ameluz® / BF-RhodoLED® for Acne

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Price target decreased to €5.50

Consensus EPS estimates fall to -€0.21

No longer forecast to breakeven

Third quarter 2021 earnings released: €0.095 loss per share (vs €0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.001 loss in 2Q 2020)

Biofrontera AG Re-Affirms Earnings Guidance for the Year 2021

Biofrontera AG Provides Update on Clinical Developments

Price target increased to €6.80

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Consensus forecasts updated

First quarter 2021 earnings released: €0.09 loss per share (vs €0.14 loss in 1Q 2020)

Price target decreased to €6.90

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2020 earnings released: €0.24 loss per share (vs €0.17 loss in FY 2019)

Biofrontera AG Provides Earnings Guidance for the Year 2021

Price target raised to €10.33

Biofrontera AG to Report Fiscal Year 2020 Final Results on Apr 12, 2021

CFO & Member of the Executive Board has left the company

Biofrontera AG Submits Study Report of Pharmacokinetics Study to FDA

New 90-day low: €2.82

Biofrontera AG Announces Management Changes

Price target raised to €8.55

New 90-day high: €3.37

New 90-day low: €2.83

Third quarter 2020 earnings released: €0.11 loss per share

New 90-day low: €2.87

Biofrontera AG Receives Reasons from the German Federal Court of Justice for Overturning Ruling of the Cologne Higher Regional Court

Biofrontera AG Reports Completion of the Clinical Phase of the Pharmacokinetics Study

Biofrontera AG Announces German Federal Supreme Court Overturns Ruling of the Cologne Higher Regional Court

Biofrontera AG(XTRA:B8F) dropped from S&P Global BMI Index

Price target raised to €7.77

Earnings released